Correspondence 0001104659-23-046710 from Adaptimmune Therapeutics PLC (ADAP) (CIK 0001621227)
Adaptimmune Therapeutics PLC (ADAP) (CIK 0001621227)
Date: April 18, 2023 · CIK: 0001621227 · Accession: 0001104659-23-046710
AI Filing Summary & Sentiment
File numbers found in text: 333-271145
Letter
April 18, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re: Adaptimmune Therapeutics plc
Amendment No. 1 to Registration Statement on Form S-4
Filed April 18, 2023
Registration No. 333-271145
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Adaptimmune Therapeutics plc (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated to, and the Registration Statement become effective on, April 20, 2023, at 4:15 P.M. Eastern Time, or as soon thereafter as practicable.
Please contact Jackie Cohen of Ropes & Gray LLP at jackie.cohen@ropesgray.com or (212) 596-9296, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely yours,
Adaptimmune Therapeutics plc
Show Raw Text
CORRESP
1
filename1.htm
April 18, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re: Adaptimmune Therapeutics plc
Amendment No. 1 to Registration Statement on Form S-4
Filed April 18, 2023
Registration No. 333-271145
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations
under the Securities Act of 1933, as amended, Adaptimmune Therapeutics plc (the “Company”) hereby requests that the
effective date of the above-referenced Registration Statement be accelerated to, and the Registration Statement become effective on, April
20, 2023, at 4:15 P.M. Eastern Time, or as soon thereafter as practicable.
Please contact Jackie Cohen of Ropes & Gray LLP at jackie.cohen@ropesgray.com
or (212) 596-9296, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely yours,
Adaptimmune Therapeutics plc
By:
/s/ Adrian Rawcliffe
Adrian Rawcliffe
Chief Executive Officer
cc: Kerry Sharp, Adaptimmune Therapeutics plc
Jackie Cohen, Ropes & Gray LLP
[Signature Page to Adaptimmune
Therapeutics plc S-4 Acceleration Request]